BridgeBio Releases PROPEL 3 Phase Data for Achondroplasia
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 hours ago
0mins
Source: Newsfilter
- Clinical Trial Success: BridgeBio's PROPEL 3 study published in NEJM shows oral infigratinib achieved an annualized height velocity of +1.74 cm/yr in children, significantly outperforming placebo (p<0.0001), providing new hope for achondroplasia treatment.
- Improvement in Body Proportionality: The study demonstrates the first statistically significant improvement in body proportionality in children with achondroplasia, particularly in those aged 3 to 8 years, with an LS mean treatment difference of -0.05 (p<0.05), marking a breakthrough in treatment efficacy.
- Good Safety Profile: Oral infigratinib showed good tolerability in the trial, with no discontinuations or serious adverse events related to the drug, and only 3 cases (4%) of mild hyperphosphatemia, indicating its potential for pediatric use.
- Future Plans: BridgeBio intends to submit an NDA to the FDA in Q3 2026, with a launch anticipated in early to mid-2027, establishing a timeline for market entry in the achondroplasia treatment landscape.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BBIO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BBIO
Wall Street analysts forecast BBIO stock price to rise
13 Analyst Rating
13 Buy
0 Hold
0 Sell
Strong Buy
Current: 69.690
Low
85.00
Averages
98.50
High
157.00
Current: 69.690
Low
85.00
Averages
98.50
High
157.00
About BBIO
BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BridgeBio Releases PROPEL 3 Phase Data for Achondroplasia
- Clinical Trial Success: BridgeBio's PROPEL 3 study published in NEJM shows oral infigratinib achieved an annualized height velocity of +1.74 cm/yr in children, significantly outperforming placebo (p<0.0001), providing new hope for achondroplasia treatment.
- Improvement in Body Proportionality: The study demonstrates the first statistically significant improvement in body proportionality in children with achondroplasia, particularly in those aged 3 to 8 years, with an LS mean treatment difference of -0.05 (p<0.05), marking a breakthrough in treatment efficacy.
- Good Safety Profile: Oral infigratinib showed good tolerability in the trial, with no discontinuations or serious adverse events related to the drug, and only 3 cases (4%) of mild hyperphosphatemia, indicating its potential for pediatric use.
- Future Plans: BridgeBio intends to submit an NDA to the FDA in Q3 2026, with a launch anticipated in early to mid-2027, establishing a timeline for market entry in the achondroplasia treatment landscape.
See More
BridgeBio Pharma Approves Employee Equity Grant Plan
- Equity Grant Plan: On June 18, 2026, BridgeBio Pharma approved equity grants totaling 66,810 restricted stock units to 30 new employees, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in genetic drug development.
- Vesting Schedule: One-fourth of each employee's restricted stock units will vest on May 16, 2027, with the remaining shares vesting quarterly, which not only incentivizes long-term employee retention but also ensures stability in key talent for the company.
- Compliance and Plan Background: The equity grants comply with Nasdaq Listing Rule 5635(c)(4) and are granted under an incentive plan adopted in November 2019, reflecting the company's commitment to employee incentive mechanisms and regulatory compliance.
- Company Mission and Development Model: BridgeBio focuses on developing transformative medicines for genetic conditions, utilizing a decentralized hub-and-spoke model designed for speed and precision to meet the medical needs of small patient populations, thereby driving sustained growth in the biopharmaceutical sector.
See More
NeOnc Secures Abu Dhabi IND Authorization for NEO212
- International Regulatory Progress: NeOnc Technologies has secured IND authorization in Abu Dhabi for its NEO212 therapy, marking a significant regulatory advancement in international markets, although it still requires further clinical studies and safety evaluations by the FDA, this progress provides an additional pathway for clinical development and may expedite future FDA discussions.
- Industry Trend Reflection: This authorization reflects a trend among biotechnology companies to pursue regulatory opportunities across multiple jurisdictions, similar to Eli Lilly's Jaypirca and Biogen's Leqembi, which have leveraged international regulatory progress to achieve expedited FDA reviews and market expansion.
- Market Potential Demonstration: While NEO212 is still in the investigational stage, its international regulatory milestone may offer NeOnc additional validation and clinical development opportunities, akin to Skyclarys' success in the rare disease space, demonstrating that therapies targeting specific diseases can still achieve substantial commercial value.
- Future Challenges Remain: Despite the authorization, NEO212 faces significant clinical, regulatory, and commercialization challenges ahead, as many therapies that receive early regulatory support ultimately fail to secure approval, thus NeOnc must continue to demonstrate meaningful benefits of its therapy for patients to ensure future success.
See More
BridgeBio Presents New Data at International Congress on Children's Bone Health
- Clinical Trial Data Presentation: BridgeBio will present positive data from the PROPEL 3 study at the 2026 International Congress on Children's Bone Health, showcasing the efficacy of oral infigratinib in children with achondroplasia, which is expected to enhance the company's market position in rare diseases.
- Multiple Research Highlights: During the conference, BridgeBio will conduct several oral presentations and poster displays covering quality of life, early intervention research, and educational resources through MyAchonJourney, aimed at raising public awareness of achondroplasia and related conditions while promoting patient education.
- Global Research Collaboration: Dr. Ravi Savarirayan, the global lead investigator for PROPEL 3, will deliver a key presentation on June 28, emphasizing the innovation of this study in treating pediatric achondroplasia, which may attract more investor interest in the company's R&D potential.
- Disease Monitoring Study Findings: BridgeBio will also showcase posters from the CLARIFY study, exploring the baseline burden of disease and quality of life in pediatric participants with autosomal dominant hypocalcemia, further solidifying its leadership in genetic disease monitoring.
See More
DKSH Partners with BridgeBio for ATTR-CM Treatment Access
- Strategic Partnership: DKSH has entered a strategic distribution partnership with BridgeBio to support regulatory evaluation and patient access for an ATTR-CM treatment in Australia, Singapore, South Korea, and Taiwan, combining BridgeBio's biotech innovation with DKSH's integrated commercialization platform.
- Market Coverage: Under the agreement, DKSH will be responsible for the distribution and commercialization of the ATTR-CM treatment in the specified countries, where the product is not yet approved, indicating a significant unmet market need that could greatly enhance patient quality of life.
- End-to-End Solutions: DKSH will leverage its expertise in regulatory affairs, medical affairs, and market access to provide comprehensive solutions prioritizing patient access, ensuring rapid launch of the new therapy following regulatory approvals.
- Vision for Growth: Patrik Grande, Global Head of DKSH Healthcare, stated that this partnership marks a new chapter for DKSH Healthcare, aiming to expand access to important new treatment options by combining scientific innovation with market expertise, advancing their mission of delivering Healthcare for All.
See More
Wall Street's Latest Ratings Overview
- DigitalOcean Coverage Initiated: KeyBanc initiates coverage of DigitalOcean with an Overweight rating and a $200 price target, indicating significant room for expansion in the cloud computing market, which could enhance its growth trajectory.
- Omnicom Growth Outlook: Goldman Sachs rates Omnicom as a Buy, highlighting an 18% free cash flow yield and organic growth in its core business, suggesting it will outperform consensus EBIT and FCF estimates, reflecting strong performance in the advertising sector.
- SSR Mining Upgrade: RBC upgrades SSR Mining from Sector Perform to Outperform, citing strategic transactions that have reduced jurisdictional risk and exceptional financial liquidity, with cash representing one-third of market cap, indicating robust future growth potential.
- Apple's Positive Outlook: Goldman Sachs reiterates a Buy rating on Apple, anticipating the announcement of an AI-enhanced Siri at the upcoming Worldwide Developers Conference, which will include several delayed features, showcasing Apple's ongoing innovation in AI technology.
See More
BridgeBio Releases PROPEL 3 Phase Data for Achondroplasia
- Clinical Trial Success: BridgeBio's PROPEL 3 study published in NEJM shows oral infigratinib achieved an annualized height velocity of +1.74 cm/yr in children, significantly outperforming placebo (p<0.0001), providing new hope for achondroplasia treatment.
- Improvement in Body Proportionality: The study demonstrates the first statistically significant improvement in body proportionality in children with achondroplasia, particularly in those aged 3 to 8 years, with an LS mean treatment difference of -0.05 (p<0.05), marking a breakthrough in treatment efficacy.
- Good Safety Profile: Oral infigratinib showed good tolerability in the trial, with no discontinuations or serious adverse events related to the drug, and only 3 cases (4%) of mild hyperphosphatemia, indicating its potential for pediatric use.
- Future Plans: BridgeBio intends to submit an NDA to the FDA in Q3 2026, with a launch anticipated in early to mid-2027, establishing a timeline for market entry in the achondroplasia treatment landscape.
See More
BridgeBio Pharma Approves Employee Equity Grant Plan
- Equity Grant Plan: On June 18, 2026, BridgeBio Pharma approved equity grants totaling 66,810 restricted stock units to 30 new employees, aimed at attracting and retaining talent, thereby enhancing the company's competitive edge in genetic drug development.
- Vesting Schedule: One-fourth of each employee's restricted stock units will vest on May 16, 2027, with the remaining shares vesting quarterly, which not only incentivizes long-term employee retention but also ensures stability in key talent for the company.
- Compliance and Plan Background: The equity grants comply with Nasdaq Listing Rule 5635(c)(4) and are granted under an incentive plan adopted in November 2019, reflecting the company's commitment to employee incentive mechanisms and regulatory compliance.
- Company Mission and Development Model: BridgeBio focuses on developing transformative medicines for genetic conditions, utilizing a decentralized hub-and-spoke model designed for speed and precision to meet the medical needs of small patient populations, thereby driving sustained growth in the biopharmaceutical sector.
See More
NeOnc Secures Abu Dhabi IND Authorization for NEO212
- International Regulatory Progress: NeOnc Technologies has secured IND authorization in Abu Dhabi for its NEO212 therapy, marking a significant regulatory advancement in international markets, although it still requires further clinical studies and safety evaluations by the FDA, this progress provides an additional pathway for clinical development and may expedite future FDA discussions.
- Industry Trend Reflection: This authorization reflects a trend among biotechnology companies to pursue regulatory opportunities across multiple jurisdictions, similar to Eli Lilly's Jaypirca and Biogen's Leqembi, which have leveraged international regulatory progress to achieve expedited FDA reviews and market expansion.
- Market Potential Demonstration: While NEO212 is still in the investigational stage, its international regulatory milestone may offer NeOnc additional validation and clinical development opportunities, akin to Skyclarys' success in the rare disease space, demonstrating that therapies targeting specific diseases can still achieve substantial commercial value.
- Future Challenges Remain: Despite the authorization, NEO212 faces significant clinical, regulatory, and commercialization challenges ahead, as many therapies that receive early regulatory support ultimately fail to secure approval, thus NeOnc must continue to demonstrate meaningful benefits of its therapy for patients to ensure future success.
See More
BridgeBio Presents New Data at International Congress on Children's Bone Health
- Clinical Trial Data Presentation: BridgeBio will present positive data from the PROPEL 3 study at the 2026 International Congress on Children's Bone Health, showcasing the efficacy of oral infigratinib in children with achondroplasia, which is expected to enhance the company's market position in rare diseases.
- Multiple Research Highlights: During the conference, BridgeBio will conduct several oral presentations and poster displays covering quality of life, early intervention research, and educational resources through MyAchonJourney, aimed at raising public awareness of achondroplasia and related conditions while promoting patient education.
- Global Research Collaboration: Dr. Ravi Savarirayan, the global lead investigator for PROPEL 3, will deliver a key presentation on June 28, emphasizing the innovation of this study in treating pediatric achondroplasia, which may attract more investor interest in the company's R&D potential.
- Disease Monitoring Study Findings: BridgeBio will also showcase posters from the CLARIFY study, exploring the baseline burden of disease and quality of life in pediatric participants with autosomal dominant hypocalcemia, further solidifying its leadership in genetic disease monitoring.
See More
DKSH Partners with BridgeBio for ATTR-CM Treatment Access
- Strategic Partnership: DKSH has entered a strategic distribution partnership with BridgeBio to support regulatory evaluation and patient access for an ATTR-CM treatment in Australia, Singapore, South Korea, and Taiwan, combining BridgeBio's biotech innovation with DKSH's integrated commercialization platform.
- Market Coverage: Under the agreement, DKSH will be responsible for the distribution and commercialization of the ATTR-CM treatment in the specified countries, where the product is not yet approved, indicating a significant unmet market need that could greatly enhance patient quality of life.
- End-to-End Solutions: DKSH will leverage its expertise in regulatory affairs, medical affairs, and market access to provide comprehensive solutions prioritizing patient access, ensuring rapid launch of the new therapy following regulatory approvals.
- Vision for Growth: Patrik Grande, Global Head of DKSH Healthcare, stated that this partnership marks a new chapter for DKSH Healthcare, aiming to expand access to important new treatment options by combining scientific innovation with market expertise, advancing their mission of delivering Healthcare for All.
See More
Wall Street's Latest Ratings Overview
- DigitalOcean Coverage Initiated: KeyBanc initiates coverage of DigitalOcean with an Overweight rating and a $200 price target, indicating significant room for expansion in the cloud computing market, which could enhance its growth trajectory.
- Omnicom Growth Outlook: Goldman Sachs rates Omnicom as a Buy, highlighting an 18% free cash flow yield and organic growth in its core business, suggesting it will outperform consensus EBIT and FCF estimates, reflecting strong performance in the advertising sector.
- SSR Mining Upgrade: RBC upgrades SSR Mining from Sector Perform to Outperform, citing strategic transactions that have reduced jurisdictional risk and exceptional financial liquidity, with cash representing one-third of market cap, indicating robust future growth potential.
- Apple's Positive Outlook: Goldman Sachs reiterates a Buy rating on Apple, anticipating the announcement of an AI-enhanced Siri at the upcoming Worldwide Developers Conference, which will include several delayed features, showcasing Apple's ongoing innovation in AI technology.
See More
